Takeda Pharmaceutical has completed its acquisition of Shire, 8 months after the deal was announced, according to a press release.
The deal was approved by 89.1% of Takeda’s shareholders and 99.8% of Shire’s shareholders, the release said.
“We are delighted that the acquisition was approved by an overwhelming majority of our shareholders at Takeda’s extraordinary general meeting on December 5, 2018. We are also pleased to have completed the acquisition several months earlier than expected, which was enabled through the hard work of our respective organizations and the
Uncategorized